
BioCryst Pharmaceuticals: A global biotech firm innovating oral treatments for rare diseases.
BioCryst Pharmaceuticals, founded in 1986, is a global biotech firm dedicated to discovering and developing novel, oral, small-molecule medicines for rare diseases where significant unmet medical needs exist. The company focuses on conditions where an enzyme plays a crucial role in the disease's biological pathway. BioCryst aims to restore a sense of freedom for patients with complement-mediated and other rare diseases through its innovative treatments. With over three decades of experience, BioCryst serves clients worldwide.
Notable affiliated individuals include key researchers and executives who have driven the company's mission forward. BioCryst has attracted significant investment from leading biotech investors, which has fueled its research and development initiatives. Key achievements include the successful development and commercialization of several groundbreaking therapies that have significantly impacted patients' lives. BioCryst's commitment to innovation and patient care has established it as a leader in the biotech industry, making substantial contributions to the treatment of rare diseases globally.

PTC Therapeutics
ptcbio.com

Catalyst Pharmaceuticals
catalystpharma.com

Krystal Biotech
krystalbio.com

BioMarin
biomarin.com

Brii Biosciences
briibio.com

Lumos Pharma
lumos-pharma.com

Attune Pharmaceuticals

Bayer Pharmaceuticals
bayer.com

Astria Therapeutics
astriatx.com

Harmony Biosciences

X4 Pharmaceuticals
x4pharma.com

Bond Biosciences
bond.bio

Amicus Therapeutics
amicusrx.com

Biomarck Pharmaceuticals

BridgeBio Pharma
bridgebio.com
Companies similar to BioCryst Pharmaceuticals include PTC Therapeutics, Catalyst Pharmaceuticals, Krystal Biotech and BioMarin.
BioCryst Pharmaceuticals was founded in 1986.
BioCryst Pharmaceuticals' headquarters is located in Durham, NC, US.
BioCryst Pharmaceuticals' most recent funding round was for $450M (USD) in April 2023.
As of Apr 17, 2023, BioCryst Pharmaceuticals has raised a total of $1.8B (USD).
BioCryst Pharmaceuticals has 531 employees as of Feb 6, 2024.